好不容易才中标的项目，企业为何选择弃标？ 今年5月，安徽省卫健委公示一则核磁共振成像系统（MR）采购公告，此后3个月7次修改招标文件，终于敲定中标结果后，中标企业却又主动弃标—— 近日，安徽省县域医共体MR采购项目的波折，揭开了医疗设备采购领域的难言之隐。 中标企业主动弃标 "这个价格是比较高的，弃标就比较怪异了。"一家头部厂商的市场推广人员刘帅（化名）看到万东医疗中标的原始公告后，感到非常惊讶。 根据安徽省招标集团股份有限公司（以下简称招标集团）8月20日发布的中标结果，万东医疗以400万元的价格，中标一套1.5T（高配）的核磁共振成像系 统。实际上，这一安徽省县域医共体MR采购项目的招标过程可谓"一波三折"——今年5月首次公开招标，随后3个月里，招标集团连续7次修改采购文件， 直到8月下旬才敲定中标结果。 | 安徽省政府采购网 | 徽省政府购买服务信息平台 | | Q 请输入内容 | 搜索 | | | | --- | --- | --- | --- | --- | --- | --- | | 首页 | 资讯动态 | 来购公告 办事指南 监督检查 | 政策法规 | 下载专区 | 购买服务 | 常见问答 | ...

医疗影像设备需求更新 20251208 摘要 2025 年核磁共振设备市场规模预计与 2024 年持平，增长停滞在 102- 103（以 2024 年为基数 100），而 CT 设备销量略有下降，预计在 97- 98 左右，需求主要集中在二级和三级医院。 DR 市场呈现萎缩趋势，预计 2025 年下降至 85-90，2026 年进一步降 至 80-85（以 2024 年为基数 100）；DSA 市场略有增长，预计 2025 年达到 107-108，2026 年可能达到 108-110，主要受益于介入手术范 围扩大和国产品牌新品推出。 PET-MR 市场规模较小，预计 2025 年 80-90 台，2026 年降至 60-70 台（以 2020 年为基数 100）；PET-CT 市场相对较好，预计 2025 年 增长 7%-8%至 107-108，2026 年达到 110。 2025 年医疗大设备整体增速约为 3%，未来两年预计小幅增长 1%- 2%，主要增量来自市一级以上的大型医院对高端产品的需求，基层医院 贡献较小，此趋势预计到 2026 年底不会发生显著变化。 集采政策在全国推广，目前约三分之一省份已进行 ...

Core Insights - The medical device distribution industry is facing significant challenges due to the expansion of centralized procurement, which has intensified price competition and reduced profit margins for distributors [2][3][4][5]. Group 1: Industry Trends - Centralized procurement for medical devices began in 2020 in Anhui and Fujian, but has recently expanded to most provinces in China, leading to a significant shift in the market landscape [2][10]. - The prices of major medical devices have drastically decreased, with examples including digital X-ray (DR) prices dropping from over 1 million to 200,000, and CT prices falling to historical lows of 600,000 [3][9]. - The ongoing anti-corruption campaign in the medical sector has heightened scrutiny on procurement practices, contributing to the rapid expansion of centralized procurement initiatives [3][12]. Group 2: Distributor Challenges - Many medical device distributors are considering transitioning to other business models, such as focusing on devices that are not yet subject to centralized procurement or moving upstream to manufacturing [4][5]. - The profit margins for distributors have significantly decreased, with some reporting earnings dropping from several million to only tens of thousands due to the competitive bidding process [4][5]. - It is projected that only about 10% of current medical device distributors will remain in the industry post-procurement expansion, primarily focusing on after-sales services [5][8]. Group 3: Manufacturer Responses - Major international manufacturers like GE and Philips are experiencing market share losses due to intensified competition from local companies, which are increasingly winning bids in centralized procurement [6][8]. - Local companies such as Wandong Medical and Mindray have shown strong performance in procurement bids, with Wandong achieving a 47% bid success rate for CT devices [8][9]. - Despite the increased competition, some manufacturers like United Imaging have managed to grow their revenue and profits, indicating that innovation may provide a competitive edge in this challenging environment [9]. Group 4: Future Outlook - The trend of centralized procurement is expected to continue expanding across provinces, with most regions likely to implement such measures within the next 3 to 5 years [12]. - The complexity of nationwide centralized procurement is acknowledged, with regional differences in medical device usage making it more feasible to conduct procurement at the provincial level [12].

Investment Rating - The report maintains a "Positive" investment rating for the medical device industry [3]. Core Insights - The medical device industry is expected to return to positive growth in 2025 after two consecutive years of decline, driven by increased demand for hospital equipment due to equipment renewal policies [9]. - The procurement amount for medical devices in October 2025 showed a year-on-year increase of 13.84% and a month-on-month increase of 0.28%, indicating a continuous recovery trend [16]. - The domestic production rate of medical devices has increased significantly from 19% in 2019 to 48% in October 2025, with varying rates across different categories [20]. Summary by Sections Equipment Procurement - The medical device procurement market is expected to reach between 187.6 billion to 241.1 billion yuan in 2025, with a strong recovery anticipated in the second half of the year [13]. - The procurement scale for October 2025 was 16.254 billion yuan, with a cumulative total of 144.665 billion yuan from January to October, reflecting a 39.63% year-on-year increase [16]. - The ultrasound procurement in October 2025 was 1.556 billion yuan, showing a 54.04% year-on-year increase, while CT procurement reached 1.996 billion yuan, up 44.06% year-on-year [25][26]. Collective Procurement - The collective procurement market in county-level areas has remained low, with a market share of 6-9% based on procurement sales from 2019 to 2024 [42]. - The overall domestic production rate in the collective procurement market reached 80% as of August 2025, indicating a significant increase driven by procurement policies [46]. - The price reduction in the county-level collective procurement market has shown a moderate trend, with the largest drop observed in monitoring devices at 57% [50].

Core Insights - The medical device industry in China is experiencing profit pressure due to centralized procurement policies, yet Siemens Healthineers has managed to achieve growth through localization and innovation [1][3][4] - Siemens Healthineers reported a 5.9% year-on-year increase in comparable revenue for the fiscal year ending September 30, 2025, with an adjusted EBIT margin of 16.5%, up 0.8 percentage points from the previous year [1][3] - The company anticipates a revenue growth of 5% to 6% for the fiscal year 2026, indicating a positive outlook despite market challenges [1][3] Industry Overview - The centralized procurement initiative in China's medical device market has intensified competition, leading to price wars and profit erosion for many manufacturers [3][4] - The market is undergoing a significant transition with a focus on large-scale equipment updates and a shift towards centralized procurement, particularly in county-level hospitals [3][4] - The medical device procurement process is still in its early stages, characterized by fragmented approaches across provinces, unclear standards, and a lack of experience [4] Company Strategy - Siemens Healthineers has implemented a "National Intelligence Innovation" localization strategy, aiming for full product line localization and deeper innovation based on market demands [4] - The company is leveraging the procurement policies to expand its market share in various provinces, supported by China's complete industrial and supply chain systems [4] - Siemens Healthineers remains optimistic about the future of the medical device market in China, particularly due to the rising demand for advanced medical equipment driven by increasing incidences of serious health conditions [5]

Core Insights - The latest financial report from the domestic medical equipment leader, United Imaging Healthcare, reveals a facade of growth that masks underlying issues such as slowing revenue growth, high accounts receivable, and declining gross margins [2][4][6] - The company is at a crossroads, facing challenges in maintaining market share and managing liquidity risks due to relaxed credit policies and industry adjustments [2][12] Financial Performance - United Imaging Healthcare reported a revenue of 6.016 billion yuan for the first half of 2025, representing a year-on-year growth of 12.79%, while the net profit attributable to shareholders increased by 21.01% to 966 million yuan [3] - The operating cash flow turned positive at 48.76 million yuan, a significant improvement from a negative 625 million yuan in the same period last year [3] Revenue Growth Concerns - The revenue growth rate of 12.79% marks a significant slowdown compared to the compound annual growth rate of 40% from 2020 to 2023, indicating a loss of the company's previous high-growth momentum [6][7] - The performance of different product lines shows a mixed picture, with MR equipment revenue growing by 16.81% to 1.968 billion yuan, while CT revenue declined by 6.37% to 1.515 billion yuan [8][9] Market Dynamics - The decline in CT revenue, a core segment for the company, raises concerns, especially as the domestic medical equipment procurement policies may be exerting downward pressure on prices [9][12] - The company has seen a notable increase in overseas revenue, which reached 1.142 billion yuan, growing by 22.48% and accounting for 18.99% of total revenue [9] Financial Health and Risks - The company's accounts receivable surged by 16.9% from 4.359 billion yuan at the end of 2024 to 5.080 billion yuan by June 2025, indicating potential issues with revenue quality [12] - Cash reserves decreased significantly from 8.4 billion yuan at the end of 2024 to 6.566 billion yuan by June 30, 2025, reflecting deteriorating financial health [12]

Core Viewpoint - By 2025, centralized procurement (集采) will become the new norm in the medical device sector, significantly impacting the entire industry chain [1] Summary by Sections Centralized Procurement Impact - In the first half of the year, the sales volume of medical devices like XP, CT, and MR in centralized procurement significantly lagged behind their sales revenue, indicating a pronounced effect of price-volume exchange [2] - The bidding rules, dominated by price, have led to continuously refreshed price floors, with examples such as 1.5T MRI machines dropping to 2 million and 64-slice CTs to over 1 million, including maintenance for 2-5 years [2] - Some devices, like DR, have seen price reductions exceeding 70%, with budget utilization in some provinces for ultrasound procurement being only in the low teens percentage-wise [2] Quality Concerns - Despite the price advantages of centralized procurement devices, hospitals express concerns about the overall service quality not keeping pace [4] - There are worries about the performance and after-sales service of low-priced devices, with industry observers noting that the price war in centralized procurement could set a price "anchor" for the retail market [5] County-Level Medical Institutions - County-level medical institutions are significant demanders in this round of equipment procurement, supported by policies aimed at improving medical device standards and quality [5] - The need for high-quality equipment and services is emphasized, as county hospitals aim to retain patients and provide comprehensive care [6][7] Equipment Lifecycle and Decision-Making - Medical devices typically have a usage cycle of 8-10 years, making the introduction of key equipment crucial for a hospital's capabilities over the next decade [9] - The total lifecycle cost of medical devices, including stability, failure rates, and after-sales service, is critical in procurement decisions [10] Training and Support - The lack of experience among medical staff in using new equipment can hinder the effective utilization of these devices, highlighting the need for training and support from manufacturers [12] - Manufacturers are encouraged to provide comprehensive services beyond just selling equipment, including training and ongoing support to enhance diagnostic capabilities [12] Regulatory and Policy Recommendations - Experts call for improved centralized procurement rules, emphasizing the need for a quality-based approach rather than solely price competition [13][15] - Recommendations include establishing a quality tracking mechanism and enhancing the evaluation criteria to include product quality, technical level, and service quality [18][17]

Core Insights - The company reported a revenue of 6.016 billion yuan for the first half of 2025, representing a year-on-year increase of 12.79%, with a net profit attributable to shareholders of 998 million yuan, up 5.03% [1] - The overseas business has shown rapid growth, with overseas revenue reaching 1.142 billion yuan, a year-on-year increase of 22.48%, accounting for 18.99% of total revenue [2] - The domestic market revenue for core product lines increased to 4.873 billion yuan, up 10.74%, with a market share increase of 3.4 percentage points in the medical imaging and radiation therapy equipment sector [3] - Service business revenue grew significantly to 816 million yuan, a 32.21% increase, with the gross margin for service business maintained above 60% [4] Group 1: Financial Performance - The company achieved a total revenue of 6.016 billion yuan in H1 2025, with a net profit of 998 million yuan [1] - In Q2 2025, revenue was 3.538 billion yuan, reflecting an 18.60% increase [1] - The adjusted net profit for H1 2025 was 966 million yuan, up 21.01% [1] Group 2: Overseas Business Growth - The overseas revenue reached 1.142 billion yuan, marking a 22.48% increase year-on-year [2] - The company has implemented a global strategy covering nearly 90 countries and regions, with strong growth in North America and Europe [2] - The company has established a global service team of over 1,000 engineers [2] Group 3: Domestic Market Performance - Domestic market revenue for H1 2025 was 4.873 billion yuan, a 10.74% increase [3] - The MR business revenue was 1.968 billion yuan, up 16.81%, with a continuous increase in market share [3] - The company’s CT business introduced innovative products, including the first photon-counting CT, which has been approved for market [3] Group 4: Service Business Expansion - Service business revenue reached 816 million yuan, a 32.21% increase, contributing to 13.56% of total revenue [4] - The overall gross margin for the company was 47.93%, with service business gross margin maintained above 60% [4] - The expansion of service business has positively impacted the company's overall profitability [4]

Core Viewpoint - The "anti-involution" policy in 2025 emphasizes the importance of drug and medical device procurement, focusing on quality and preventing irrational pricing in the medical industry [1][2]. Group 1: Drug Procurement Policy Changes - The government work report highlights the need to optimize drug and consumable procurement policies, enhancing quality assessment and regulation to ensure safer medication for the public [1]. - The 11th batch of drug procurement initiated in July marks a significant policy shift, reinforcing quality supervision and optimizing price control rules, moving away from the lowest price as a benchmark [1][2]. Group 2: Medical Device Procurement Challenges - The current medical device procurement is still in a trial phase, requiring a robust policy framework and operational guidelines to avoid the pitfalls of low-price bidding, which can compromise quality and profitability [2][4]. - Instances of "super low-price winning bids" in medical device procurement have raised concerns about sustainability and quality, with some bids significantly below production costs [4][5]. Group 3: Quality Assessment and Lifecycle Considerations - Experts emphasize that quality assessment for medical devices should consider the entire lifecycle, as initial low prices may lead to higher long-term costs due to maintenance and performance issues [5][6]. - Hospitals are cautious in procuring medical devices, often conducting thorough evaluations of performance and service quality before making decisions, indicating that price should not be the sole consideration [6]. Group 4: Regulatory Framework and Standardization - The lack of a comprehensive regulatory framework for medical device procurement contrasts with the more established guidelines for drug procurement, leading to a reliance on price competition without adequate quality controls [8][9]. - Recent initiatives in various provinces aim to standardize procurement processes, but a national-level regulatory framework is still needed to guide improvements in medical device procurement [10][12]. Group 5: Industry Development and Innovation - The domestic medical device industry is at a critical stage of innovation and development, with a significant gap in R&D investment compared to international leaders, which could be exacerbated by low-price competition [13][14]. - The high-end medical equipment sector is still catching up, with domestic brands holding approximately 45% market share in CT devices and 40% in MRI devices, indicating room for growth and innovation [14]. Group 6: Future Directions and Recommendations - Industry stakeholders advocate for a shift in procurement evaluation criteria from price-centric to a multi-dimensional assessment that includes technical capabilities, service quality, and product reliability [15]. - Establishing a tracking and accountability mechanism for procurement outcomes is essential to ensure compliance with quality commitments and to prevent low-quality products from disrupting the market [15].

Core Viewpoint - The phenomenon of "ultra-low price bidding" in medical device procurement is raising concerns about potential hidden waste and increased financial burden, prompting the National Healthcare Security Administration to clarify that procurement will no longer solely rely on the lowest price as a reference [1][3]. Group 1: Impact of Low Price Bidding - The aim of centralized procurement is to eliminate price inflation and ensure efficient use of fiscal funds, but the frequent occurrence of "ultra-low price bidding" may lead to hidden waste and increased financial burdens [3][5]. - The strategy of "lowest price wins" can force companies to cut core configurations, use lower-grade components, or compromise quality control, leading to wasted resources and equipment that may be unusable [3][5]. - Reports indicate that some grassroots hospitals have a medical device usage rate of less than 40%, often due to rigid procurement practices that prioritize low prices over quality, resulting in poor performance or complex operations that lead to abandonment [3][5]. Group 2: Long-term Industry Consequences - The long-term harm of the "lowest price" strategy to the medical device industry is significant, as companies may resort to extreme low pricing to survive, undermining the industry's pricing structure and stifling innovation [5][6]. - Continuous low-price competition is depleting the industry's capacity for innovation and may ultimately harm product quality and healthcare service levels, hindering the industry's transition to higher-end development [5][6]. - This short-sighted strategy can lead to a "technical disconnection," where the industry loses its ability to advance technologically and maintain future competitiveness [5][6]. Group 3: Quality and Service in Procurement - The quality of low-priced devices is often questionable, with issues such as poor image quality, insufficient diagnostic accuracy, and missing functions, which can jeopardize patient health [7][9]. - To address the challenges posed by the "lowest price" approach, establishing a "quality for price" orientation has become a core concern of procurement policy, with ongoing efforts to optimize mechanisms at the national level [7][9]. - The characteristics of "good devices" needed in procurement are becoming clearer, focusing on superior quality performance, excellent clinical adaptability, and a reliable after-sales service system [9][10]. Group 4: Industry Innovation and Future Outlook - Leading companies in the industry are accelerating innovation around these standards, utilizing AI algorithms to optimize manufacturing processes and enhance product quality and service capabilities [10]. - Future procurement will favor manufacturers that can meet stringent quality performance standards, accurately match diverse clinical needs, and provide reliable long-term after-sales support [10].